Form D · Biotechnology
Osmol Therapeutics, Inc.
New Haven, CT · CIK 0001694244
Offering snapshot reported Feb 28, 2022 · SEC filing
- Reported sold
- $2.3M Offering amount: $7.5M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 28, 2022 | Initial | $2,300,000 | No comparison | 4 | SEC filing |
| Jan 18, 2017 | Initial | $550,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-435142
Source: Form D, filed Feb 28, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Berman | Director |
| Vlad Coric | Director |
| Brian Dixon | Director, Executive |
| Michael Ehrlich | Director |
| Robert Linke | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
33 Whitney Avenue Suite 2 B
New Haven, CT, 06510
New Haven, CT, 06510